Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada
MWN-AI** Summary
Clearside Biomedical, Inc. recently announced that Health Canada has approved XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in treating uveitic macular edema (UME). This approval extends the product's availability, which is already approved in the United States, Australia, and Singapore, with further regulatory reviews in China ongoing.
XIPERE is a proprietary formulation designed for administration into the suprachoroidal space, enabling targeted treatment for macular edema related to uveitis. The U.S. commercialization and development rights are held by Bausch + Lomb, while Arctic Vision manages its development in Greater China and other Asia-Pacific regions.
A key component of Clearside’s innovation is its patented Suprachoroidal Space (SCS) injection platform, which employs the SCS Microinjector®. This unique injection system allows for the focused delivery of therapies to the eye’s back, potentially improving treatment efficacy while minimizing side effects on non-diseased tissues. The SCS Microinjector uses a sophisticated design boasting two hollow microneedles, optimizing drug delivery.
Clearside Biomedical, based in Alpharetta, Georgia, aims to enhance patient outcomes by providing innovative delivery systems that bypass traditional methods. The company is also advancing its pipeline with products like CLS-AX (axitinib injectable suspension), which is poised for Phase 3 trials for treating wet age-related macular degeneration (AMD).
In summary, the approval of XIPERE in Canada underscores Clearside's commitment to expanding its global reach and validating its innovative treatment platform. As the company continues to pursue partnerships and new developments, it remains focused on addressing critical needs in ocular health and disease management.
MWN-AI** Analysis
The recent approval of Clearside Biomedical’s XIPERE® in Canada for treating uveitic macular edema marks a significant milestone for the company, further validating its innovative suprachoroidal space (SCS) injection platform. As XIPERE gains traction across multiple global markets, including recent approvals in Australia and Singapore, investors should view this expansion as a pivotal moment for Clearside, particularly given its unique delivery method that enhances drug efficacy while minimizing side effects.
With Bausch + Lomb holding exclusive commercialization rights in the U.S. and Canada and Arctic Vision managing its deployment in Greater China and surrounding regions, Clearside's strategy leverages strong partnerships that bolster market penetration. The continued global expansion of XIPERE suggests a robust pipeline for revenue growth, especially as the product undergoes regulatory review in China, a potentially lucrative market for ophthalmic therapies.
Investors should be mindful of the competitive landscape in ophthalmic biopharma, where innovation drives success. Clearside's proprietary SCS Microinjector® may soon become a benchmark in targeted ocular therapies, positioning the company favorably against rivals. Moreover, with its ongoing development of CLS-AX for the treatment of wet AMD, Clearside could diversify its portfolio and enhance its market resilience.
However, it is essential to remain cautious of the inherent risks mentioned in their statements, including reliance on clinical trial outcomes and third-party collaborations. Market volatility and capital requirements could influence the stock price.
In summary, Clearside Biomedical appears well-positioned for growth in the ophthalmology space, particularly with the successful rollout of XIPERE. Investors looking for opportunities in the biotech sector should consider the potential upside, while carefully weighing the accompanying risks associated with this innovative company’s future endeavors.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- XIPERE Now Approved for Use in Multiple Global Markets -
- Continued Global Expansion and Validation of Clearside’s Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector ® -
ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that Health Canada has granted approval for XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME).
XIPERE is approved for use in the United States, Canada, Australia, and Singapore and under regulatory review in China.
About XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use
XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use is a proprietary suspension of the corticosteroid triamcinolone acetonide for administration to the suprachoroidal space for the treatment of macular edema associated with uveitis. XIPERE is approved by the U.S. Food and Drug Administration and is commercially available in the United States. Bausch + Lomb, a leading global eye health company dedicated to helping people see better to live better, has the exclusive license for the commercialization and development of XIPERE in the U.S. and Canada. Arctic Vision, a China-based ophthalmic biotech, has the exclusive license for the commercialization and development of XIPERE, which they refer to as ARCATUS ® or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries.
About Clearside’s Suprachoroidal Space (SCS ® ) Injection Platform and SCS Microinjector ®
Clearside’s patent protected, proprietary suprachoroidal space (SCS ® ) injection treatment approach offers unprecedented access to the back of the eye, where sight-threatening disease often occurs. The Company’s unique platform is inherently flexible and intended to work with established and new formulations of medications. Clearside’s patented SCS Microinjector ® can deliver a wide variety of drug candidates into the suprachoroidal space, providing targeted delivery to potentially improve efficacy and compartmentalization of medication to reduce or eliminate toxic effects on non-diseased cells. The SCS Microinjector is comprised of a syringe with a custom-designed hub and two 30-gauge hollow microneedles of varying lengths, each approximately one millimeter, optimizing insertion and suprachoroidal administration of drugs.
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ) to improve patient outcomes. Clearside’s SCS injection platform, utilizing the Company’s patented SCS Microinjector ® , enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a wide variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. Clearside has a pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company’s lead program, CLS-AX (axitinib injectable suspension) , is a Phase 3 ready asset for the treatment of neovascular age-related macular degeneration (wet AMD). Clearside developed and gained approval for its first product, XIPERE ® (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the U.S. through a commercial partner. Clearside also strategically partners its SCS injection platform with companies utilizing other ophthalmic therapeutic innovations. For more information, please visit clearsidebio.com or follow us on LinkedIn and X .
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “believe”, “expect”, “may”, “plan”, “potential”, “will”, and similar expressions, and are based on Clearside’s current beliefs and expectations. These forward-looking statements include statements regarding the clinical development of Clearside’s product candidates, and the potential benefits of CLS-AX and XIPERE ® , Clearside’s suprachoroidal delivery technology and Clearside’s SCS Microinjector ® . These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Clearside’s reliance on third parties over which it may not always have full control, Clearside's ability to raise additional capital, and other risks and uncertainties that are described in Clearside’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (SEC) on March 27, 2025, and Clearside’s other periodic reports filed with the SEC. Any forward-looking statements speak only as of the date of this press release and are based on information available to Clearside as of the date of this release, and Clearside assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Source: Clearside Biomedical, Inc.
Investor and Media Contacts:Jenny KobinRemy Bernardair@clearsidebio.com
FAQ**
How does the approval of XIPERE by Health Canada impact Clearside Biomedical Inc. CLSD’s market strategy and potential revenue in Canada compared to the U.S. market where it is already commercially available?
With XIPERE now approved in multiple global markets, what are Clearside Biomedical Inc. CLSD's plans for further expanding its presence in regions yet to be explored, particularly in China where regulatory review is ongoing?
Can you elaborate on how the SCS Microinjector™ technology enhances the efficacy of XIPERE treatment while minimizing toxic effects on non-diseased cells, and what this means for Clearside Biomedical Inc. CLSD's competitive advantage?
What are the anticipated timelines and major milestones for Clearside Biomedical Inc. CLSD’s pipeline products, especially CLS-AX for neovascular age-related macular degeneration, following the success of XIPERE in the marketplace?
**MWN-AI FAQ is based on asking OpenAI questions about Clearside Biomedical Inc. (NASDAQ: CLSD).
NASDAQ: CLSD
CLSD Trading
-90.6% G/L:
$0.41 Last:
1,945,057 Volume:
$0.57 Open:
